Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.
Actively Recruiting
This research aims to evaluate the effectiveness and safety of an investigational eye drop solution called Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preservative Free, compared to a placebo vehicle solution in adults experiencing eye redness due to minor irritations. The study targets adults with ocular redness and focuses on measuring changes in redness after treatment. It is a Phase 3, randomized, double-blind clinical trial sponsored by Alcon Research. Participants will receive a single dose of the study treatment, one drop in each eye on Day 1. The study includes two groups one receiving the investigational Apraclonidine solution and the other receiving a vehicle placebo. The treatment is given during an in-office visit, and eye redness is assessed before and after instillation at specific timepoints on Day 1 and Day 2. Participants are expected to attend three in-office visits over about one week. Assessments include investigator-rated redness scores at baseline and at several times after treatment, including 1 minute, 15 minutes, 14 hours, and 16 hours post-instillation. Safety and efficacy are monitored through these evaluations. The total study period covers from treatment through follow-up assessments, concluding around one week after the first dose.
Actively Recruiting
Researchers are evaluating the safety, how the body absorbs and processes, and the treatment effects of CABTREO lotion when applied to the skin in children aged 9 to 11 years, 11 months who have moderate to severe acne vulgaris. The study is open-label and phase 4, focusing on pediatric participants with specific acne severity and lesion counts on the face and at least one trunk area. The purpose is to understand how well CABTREO works and how safe it is in this age group. Participants will apply CABTREO, a combination gel containing clindamycin phosphate 1.2%, benzoyl peroxide 3.1%, and adapalene 0.15%, to affected areas once each morning for 12 weeks. On study visit days, participants will apply the gel at the study center after assessments. The study includes a main group and a smaller pharmacokinetics PK sub-study group to examine drug levels in the blood. The treatment is a topical gel gently rubbed into the skin. Participants will first complete a screening period of up to 5 weeks to confirm eligibility. During the 12-week treatment, they will attend visits at baseline and Days 14, 15 PK sub-study only, 28, 29 PK sub-study only, 56, and 84. Researchers will monitor safety by tracking any adverse events and measure changes in inflammatory and non-inflammatory acne lesions, as well as global acne severity scores. Participants must follow study instructions and attend visits with their parent or guardian if under age of consent.